Infection with human papillomavirus (HPV) is one of the most common sexually transmitted infections. Persistent HPV infection can cause anogenital cancer, oropharyngeal cancers and cervical cancer. While prophylactic HPV vaccination and cervical cancer screening are effective in preventing most HPV infection and cervical cancer, there remains important gaps in knowledge on the immunology of HPV tumorigenesis and HPV vaccines. These include the immune responses against HPV infection and persistence in different anatomical sites, as well as the role of HPV proteins (i.e. E5, E6 and E7) and microRNAs in regulating the microenvironment. Furthermore, while HPV vaccine has proved to be effective in healthy populations, the evidence of their efficacy and immunogenicity are less clear in high-risk groups such as men who have sex with men (MSM), HIV-infected individuals as well as women who were treated for pre-cancer or cervical cancer lesions and are at risk of recurrence diseases. One of the biggest barriers to the introduction of HPV vaccine is its high cost. Accurate burden data and cost effectiveness analysis is needed to support its introduction at country level.
The aim of this Research Topic is to provide a forum to advance research on the natural history of HPV in different populations, the HPV-related immunological response and optimal immunization strategies to enable better therapeutics and preventative strategies, and ultimately contributing to the reduction of HPV-associated morbidities and to the global action of eliminating cervical cancer in the coming century.
We welcome submissions of Original Research, Review and Mini Review on the subtopics below:
• HPV vaccination in MSM
• The natural history of HPV in men in different settings
• Longitudinal studies that clarify the natural history of HPV antibodies after infection
• The long-term clinical effectiveness of HPV vaccine and vaccine efficacy among special populations, people living with HIV in particular
• Modelling study on HPV vaccination strategies
• Humoral immune response to HPV infection and effect of naturally acquired HPV antibodies
• The innate and adaptive immunity involved in HPV associated cancer at different sites
• Role of B cells in HPV-related cancer therapy.
• The role of miRNA in HPV positive-cancer immune microenvironment
• Immunological studies on HPV co-infection with other diseases such as HIV, hepatitis, tuberculosis, and COVID-19.
• Cost-effectiveness studies on HPV vaccination in HIV-infected women
• Cost-effectiveness studies on HPV vaccination in women after treatment for cervical precancerous lesions
• HPV genotype replacement in populations with a high coverage of HPV vaccination
Infection with human papillomavirus (HPV) is one of the most common sexually transmitted infections. Persistent HPV infection can cause anogenital cancer, oropharyngeal cancers and cervical cancer. While prophylactic HPV vaccination and cervical cancer screening are effective in preventing most HPV infection and cervical cancer, there remains important gaps in knowledge on the immunology of HPV tumorigenesis and HPV vaccines. These include the immune responses against HPV infection and persistence in different anatomical sites, as well as the role of HPV proteins (i.e. E5, E6 and E7) and microRNAs in regulating the microenvironment. Furthermore, while HPV vaccine has proved to be effective in healthy populations, the evidence of their efficacy and immunogenicity are less clear in high-risk groups such as men who have sex with men (MSM), HIV-infected individuals as well as women who were treated for pre-cancer or cervical cancer lesions and are at risk of recurrence diseases. One of the biggest barriers to the introduction of HPV vaccine is its high cost. Accurate burden data and cost effectiveness analysis is needed to support its introduction at country level.
The aim of this Research Topic is to provide a forum to advance research on the natural history of HPV in different populations, the HPV-related immunological response and optimal immunization strategies to enable better therapeutics and preventative strategies, and ultimately contributing to the reduction of HPV-associated morbidities and to the global action of eliminating cervical cancer in the coming century.
We welcome submissions of Original Research, Review and Mini Review on the subtopics below:
• HPV vaccination in MSM
• The natural history of HPV in men in different settings
• Longitudinal studies that clarify the natural history of HPV antibodies after infection
• The long-term clinical effectiveness of HPV vaccine and vaccine efficacy among special populations, people living with HIV in particular
• Modelling study on HPV vaccination strategies
• Humoral immune response to HPV infection and effect of naturally acquired HPV antibodies
• The innate and adaptive immunity involved in HPV associated cancer at different sites
• Role of B cells in HPV-related cancer therapy.
• The role of miRNA in HPV positive-cancer immune microenvironment
• Immunological studies on HPV co-infection with other diseases such as HIV, hepatitis, tuberculosis, and COVID-19.
• Cost-effectiveness studies on HPV vaccination in HIV-infected women
• Cost-effectiveness studies on HPV vaccination in women after treatment for cervical precancerous lesions
• HPV genotype replacement in populations with a high coverage of HPV vaccination
